The Fecal Incontinence drugs in development market research report provides comprehensive information on the therapeutics under development for Fecal Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fecal Incontinence. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fecal Incontinence and features dormant and discontinued products.
GlobalData tracks five drugs in development for Fecal Incontinence by five companies/universities/institutes. The top development phase for Fecal Incontinence is phase i with two drugs in that stage. The Fecal Incontinence pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Fecal Incontinence pipeline products market are: Anterogen, Astellas Pharma and Cook MyoSite.
The key targets in the Fecal Incontinence pipeline products market include Alpha 1 Adrenergic Receptor (ADRA1), and 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3).
The key mechanisms of action in the Fecal Incontinence pipeline product include Alpha 1 Adrenergic Receptor (ADRA1) Agonist with one drug in Phase II. The Fecal Incontinence pipeline products include seven routes of administration with the top ROA being Intramuscular and two key molecule types in the Fecal Incontinence pipeline products market including Cell Therapy, and Small Molecule.
Fecal Incontinence overview
Fecal incontinence (also called anal or bowel incontinence) is the impaired ability to control the passage of gas or stool. This can range from an infrequent involuntary passage of small amounts of stool to a total loss of bowel control. Common causes of fecal incontinence include diarrhea, constipation, and muscle or nerve damage. The muscle or nerve damage may be associated with aging or with giving birth
For a complete picture of Fecal Incontinence’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
